75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation ...
MedPage Today on MSN
Targeted Drug for Advanced Pancreatic Cancer Sparks Early Enthusiasm
SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...
Phase 1b trial shows 40% response rate for onvansertib plus paclitaxel in metastatic triple-negative breast cancer, with manageable toxicity. Cardiff Oncology, Inc. announced promising results from a ...
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 ...
SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced ...
Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS). An ...
The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback